Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir

Kevin P. Vo, Philip Vutien, Matthew J. Akiyama, Vinh D. Vu, Nghiem B. Ha, Joy I. Piotrowski, James Wantuck, Marina M. Roytman, Naoky Tsai, Ramsey Cheung, Jiayi Li, Mindie H. Nguyen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: There are limited data analyzing the effectiveness of boceprevir (BOC) or telaprevir (TVR) in combination with pegylated interferon (PEG-IFN) plus ribavirin (RBV) in a real-life patient cohort. Aims: In clinical trials, patients with chronic hepatitis C (CHC) treated with BOC or TVR plus PEG-IFN and RBV achieved sustained virological response (SVR) rates of 70 %. However, it is not clear whether similar results can be realized in routine practice. Our goal is to examine SVR rates of these triple regimens for CHC in a multicenter real-life patient cohort. Methods: We retrospectively studied 200 consecutive CHC genotype 1 patients who were initiated on PEG-IFN, RBV, and either TVR (n = 113) or BOC (n = 87) from July 2011 to February 2014 at two US academic liver clinics, a Veterans Affairs liver clinic and a community gastroenterology clinic. Results: Both BOC and TVR treatment groups were similar in regard to comorbidities, BMI, and HCV RNA levels. BOC patients were more likely to have cirrhosis than TVR patients (47 vs. 24 %, P = 0.001). SVR rates were low in both cohorts (40 % for BOC, 53 % for TVR, P = 0.05). On multivariate logistic regression, treatment adherence by the “80/80/80 rule,” diagnosis of cirrhosis, and use of erythropoietin were statistically significant predictors for SVR. Of these, treatment adherence was the strongest predictor (OR 4.43, 95 % CI 2.8–6.06, P 

Original languageEnglish (US)
Pages (from-to)1045-1051
Number of pages7
JournalDigestive Diseases and Sciences
Volume60
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Ribavirin
Chronic Hepatitis C
Interferons
Fibrosis
Liver
Veterans
Gastroenterology
Erythropoietin
telaprevir
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
Comorbidity
Therapeutics
Logistic Models
Genotype
Clinical Trials
RNA

Keywords

  • BOC
  • Effectiveness
  • HCV
  • PEG-IFN
  • Routine practice
  • TVR

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology
  • Medicine(all)

Cite this

Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. / Vo, Kevin P.; Vutien, Philip; Akiyama, Matthew J.; Vu, Vinh D.; Ha, Nghiem B.; Piotrowski, Joy I.; Wantuck, James; Roytman, Marina M.; Tsai, Naoky; Cheung, Ramsey; Li, Jiayi; Nguyen, Mindie H.

In: Digestive Diseases and Sciences, Vol. 60, No. 4, 01.04.2015, p. 1045-1051.

Research output: Contribution to journalArticle

Vo, Kevin P. ; Vutien, Philip ; Akiyama, Matthew J. ; Vu, Vinh D. ; Ha, Nghiem B. ; Piotrowski, Joy I. ; Wantuck, James ; Roytman, Marina M. ; Tsai, Naoky ; Cheung, Ramsey ; Li, Jiayi ; Nguyen, Mindie H. / Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir. In: Digestive Diseases and Sciences. 2015 ; Vol. 60, No. 4. pp. 1045-1051.
@article{5daa5ba0a4f6470daaee0a2b7f93c79f,
title = "Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir",
abstract = "Background: There are limited data analyzing the effectiveness of boceprevir (BOC) or telaprevir (TVR) in combination with pegylated interferon (PEG-IFN) plus ribavirin (RBV) in a real-life patient cohort. Aims: In clinical trials, patients with chronic hepatitis C (CHC) treated with BOC or TVR plus PEG-IFN and RBV achieved sustained virological response (SVR) rates of 70 {\%}. However, it is not clear whether similar results can be realized in routine practice. Our goal is to examine SVR rates of these triple regimens for CHC in a multicenter real-life patient cohort. Methods: We retrospectively studied 200 consecutive CHC genotype 1 patients who were initiated on PEG-IFN, RBV, and either TVR (n = 113) or BOC (n = 87) from July 2011 to February 2014 at two US academic liver clinics, a Veterans Affairs liver clinic and a community gastroenterology clinic. Results: Both BOC and TVR treatment groups were similar in regard to comorbidities, BMI, and HCV RNA levels. BOC patients were more likely to have cirrhosis than TVR patients (47 vs. 24 {\%}, P = 0.001). SVR rates were low in both cohorts (40 {\%} for BOC, 53 {\%} for TVR, P = 0.05). On multivariate logistic regression, treatment adherence by the “80/80/80 rule,” diagnosis of cirrhosis, and use of erythropoietin were statistically significant predictors for SVR. Of these, treatment adherence was the strongest predictor (OR 4.43, 95 {\%} CI 2.8–6.06, P ",
keywords = "BOC, Effectiveness, HCV, PEG-IFN, Routine practice, TVR",
author = "Vo, {Kevin P.} and Philip Vutien and Akiyama, {Matthew J.} and Vu, {Vinh D.} and Ha, {Nghiem B.} and Piotrowski, {Joy I.} and James Wantuck and Roytman, {Marina M.} and Naoky Tsai and Ramsey Cheung and Jiayi Li and Nguyen, {Mindie H.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s10620-015-3621-0",
language = "English (US)",
volume = "60",
pages = "1045--1051",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "4",

}

TY - JOUR

T1 - Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir

AU - Vo, Kevin P.

AU - Vutien, Philip

AU - Akiyama, Matthew J.

AU - Vu, Vinh D.

AU - Ha, Nghiem B.

AU - Piotrowski, Joy I.

AU - Wantuck, James

AU - Roytman, Marina M.

AU - Tsai, Naoky

AU - Cheung, Ramsey

AU - Li, Jiayi

AU - Nguyen, Mindie H.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background: There are limited data analyzing the effectiveness of boceprevir (BOC) or telaprevir (TVR) in combination with pegylated interferon (PEG-IFN) plus ribavirin (RBV) in a real-life patient cohort. Aims: In clinical trials, patients with chronic hepatitis C (CHC) treated with BOC or TVR plus PEG-IFN and RBV achieved sustained virological response (SVR) rates of 70 %. However, it is not clear whether similar results can be realized in routine practice. Our goal is to examine SVR rates of these triple regimens for CHC in a multicenter real-life patient cohort. Methods: We retrospectively studied 200 consecutive CHC genotype 1 patients who were initiated on PEG-IFN, RBV, and either TVR (n = 113) or BOC (n = 87) from July 2011 to February 2014 at two US academic liver clinics, a Veterans Affairs liver clinic and a community gastroenterology clinic. Results: Both BOC and TVR treatment groups were similar in regard to comorbidities, BMI, and HCV RNA levels. BOC patients were more likely to have cirrhosis than TVR patients (47 vs. 24 %, P = 0.001). SVR rates were low in both cohorts (40 % for BOC, 53 % for TVR, P = 0.05). On multivariate logistic regression, treatment adherence by the “80/80/80 rule,” diagnosis of cirrhosis, and use of erythropoietin were statistically significant predictors for SVR. Of these, treatment adherence was the strongest predictor (OR 4.43, 95 % CI 2.8–6.06, P 

AB - Background: There are limited data analyzing the effectiveness of boceprevir (BOC) or telaprevir (TVR) in combination with pegylated interferon (PEG-IFN) plus ribavirin (RBV) in a real-life patient cohort. Aims: In clinical trials, patients with chronic hepatitis C (CHC) treated with BOC or TVR plus PEG-IFN and RBV achieved sustained virological response (SVR) rates of 70 %. However, it is not clear whether similar results can be realized in routine practice. Our goal is to examine SVR rates of these triple regimens for CHC in a multicenter real-life patient cohort. Methods: We retrospectively studied 200 consecutive CHC genotype 1 patients who were initiated on PEG-IFN, RBV, and either TVR (n = 113) or BOC (n = 87) from July 2011 to February 2014 at two US academic liver clinics, a Veterans Affairs liver clinic and a community gastroenterology clinic. Results: Both BOC and TVR treatment groups were similar in regard to comorbidities, BMI, and HCV RNA levels. BOC patients were more likely to have cirrhosis than TVR patients (47 vs. 24 %, P = 0.001). SVR rates were low in both cohorts (40 % for BOC, 53 % for TVR, P = 0.05). On multivariate logistic regression, treatment adherence by the “80/80/80 rule,” diagnosis of cirrhosis, and use of erythropoietin were statistically significant predictors for SVR. Of these, treatment adherence was the strongest predictor (OR 4.43, 95 % CI 2.8–6.06, P 

KW - BOC

KW - Effectiveness

KW - HCV

KW - PEG-IFN

KW - Routine practice

KW - TVR

UR - http://www.scopus.com/inward/record.url?scp=84934267879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934267879&partnerID=8YFLogxK

U2 - 10.1007/s10620-015-3621-0

DO - 10.1007/s10620-015-3621-0

M3 - Article

C2 - 25821099

AN - SCOPUS:84934267879

VL - 60

SP - 1045

EP - 1051

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 4

ER -